Please refer to attachment.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Glycols Limited reported strong FY2026 results with standalone PAT growing 56.5% to Rs 282.33 crore from Rs 180.38 crore in FY2025. Revenue from operations increased 8.7% to Rs 9,826.20 crore. EBITDA rose 32.4% to Rs 690.09 crore with margin expansion of approximately 168 basis points. The company completed a preferential issue raising Rs 467 crore in November 2025, and a stock split was executed in August 2025 (face value reduced from Rs 10 to Rs 5). A demerger scheme for the Bio Pharma and Spirits & Biofuel undertaking is pending NCLT approval with next hearing on May 21, 2026. Auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
The company delivered robust profit growth well above the 25% threshold with EBITDA margin expansion, indicating improved operational efficiency. The Rs 467 crore capital raise strengthens the balance sheet. The pending demerger could unlock value for shareholders if approved by NCLT.